Navigation Links
Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells

An estrogen-like chemical commonly used to synthesize plastic food containers has been shown to encourage the growth of a specific category of prostate cancer cell, potentially affecting the treatment efficacy for a subset of prostate cancers. According to a study published in the January 1 issue of Cancer Research, such prostate cancer cells proved to be vulnerable to exposure to the chemical BPA (bisophenol A), an industrial chemical and nonsteroidal environmental estrogen used in the manufacture of food cans, milk container linings, food storage containers and water supply pipes. About 2.5 billion pounds of the chemical are produced each year.

In particular, the study showed that the affected class of prostate cancer cell, characterized by mutated receptors for androgens, the male hormone, can proliferate in response to BPA. “The results may have implications for men who develop BPA-susceptible mutations in their androgen receptor genes during the course of prostate cancer treatment, although these concepts will need to be verified in animal systems,?according to Karen Knudsen, Ph.D., an assistant professor in the University of Cincinnati’s Department of Cell Biology and Center for Environmental Genetics. Scientists estimate that anywhere from eight to 25 percent of all prostate cancer patients may fall into this category. In the United States alone this year, almost 220,000 men will be diagnosed with prostate cancer. The disease is the second most common type of cancer found in American men, and approximately 29,000 men will die from prostate cancer this year. Many cases of prostate cancer depend on androgens like testosterone for tumor growth and cancer cell proliferation, said Dr. Knudsen, the study’s senior author. A common treatment for prostate cancer includes limiting testosterone synthesis. Patients with mutated androgen receptors may not respond to this therapy and according to this new study, exposure to BPA among these patients could potentially put them at higher risk for increased cancer cell growth. “The results we see in cell culture in response to BPA are ready to be moved to appropriate animal models next,?said Dr. Knudsen. The effect of the environmental non-steroidal BPA on human prostate cancer tumor implants in laboratory animal models will shed additional light on whether the synthetic pseudo-estrogen encourages tumor growth in whole animal systems. “We’ll know more about the ‘hormone sensitizing?ability of BPA in prostate cancer cells from studies on animals. It is also important to note that our study demonstrates that the actual dose of BPA exposure may change the biological response,?Dr. Knudsen said. The safety of BPA has been under intense debate for several years, with some arguing that exposure to the chemical among humans is safe, with others contending that it may promote the growth of human tumor cells and alter the growth and development of animals.
'"/>

Source:American Association for Cancer Research


Related biology news :

1. Component in soy products causes reproductive problems in laboratory mice
2. Brain May Be Less Plastic Than Hoped
3. Plastic surgeons countdown first full facial transplantation
4. Whats next for gene therapy? Plastic
5. Plastic that degrades in seawater could be boon for cruise industry and others
6. New Research Shows Artificial Light at Night Stimulates Breast Cancer Growth in Laboratory Mice
7. Growth in the sea comes down to a struggle for iron
8. Growth in biomass could put US on road to energy independence
9. Embryonic Stem Cells Treated With Growth Factor Reverse Hemophilia In Mice: UNC Researchers
10. Missing Receptor Molecule Causes Tumor Growth
11. Growth hormone is made in the brain, report scientists

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma A/S ... innovative TransCon technology to address significant unmet medical ... for the full year ended December 31, 2016. ... for our company as we broadened our pipeline ... integrated rare disease company with an initial focus ...
(Date:3/22/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... ), a clinical-stage pharmaceutical company focused on the ... that Dr. Miriam Kidron , Oramed,s Chief ... Insulin for Diabetes Treatment: Bypassing the Roadblock," at ... Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts ...
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... 2017   VWR (NASDAQ: VWR), ... and service solutions to laboratory and production ... EPL Archives, Inc., an international biorepository services ... regulated product research, development and commercialization lifecycle ... ancillary services. EPL Archives is widely recognized ...
Breaking Biology Technology: